TACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial.

NCT ID: NCT06887413

Last Updated: 2025-11-25

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 140 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-15
• Study Completion Date: 2027-07-01

Brief Summary

The aim of this study is to evaluate the impact of sustained thrombectomy with INDIGO ASPIRATION SYSTEM using CAT RX versus no thrombectomy during primary percutaneous coronary intervention (PPCI) on microvascular obstruction and infarct size, as measured by cardiovascular magnetic resonance (CMR) between 3 and 5 days post PPCI, in patients with anterior STEMI

Detailed Description

Prospective, randomized 1:1, controlled, open label, multicentred, investigator initiated clinical investigation in 14 European sites. 140 patients will be enrolled in the study after coronary angiography confirming prox or mid LAD occlusion. Patients will be randomised in one of the following arms:

Treatment arm: Subjects randomized to the treatment arm will be treated with the CAT RX as previously described.

Control arm: Subjects randomized to the control arm will be treated with standard PPCI .

Participants will undergo a cardiac MRI, including gadolinium contrast imaging, within 3-5 days following the index procedure. If clinical contraindications prevent the MRI from being performed within this timeframe, it should be conducted as soon as the participant is clinically stable.

After the discharge, In-person or phone follow-ups will take place at 30 days, and 12 months post-PCI.

Primary endpoint will be measured at 3-5 days post procedure where a microvascular obstruction will be assed by CMR mass.

Secondary endpoints will be assessed: Secondary CMR endpoint - measured at 3-5 days post PPCI:Infarct size, as a percent of LV mass

• Left ventricular end-systolic volume (LVESV)
• Left ventricular end-diastolic volume (LVEDV)
• Left ventricular end-systolic volume index
• Left ventricular end-diastolic volume index
• Ejection fraction (EF)

Secondary exploratory clinical and angiographic endpoint:

Measured at the end of the procedure:

• TIMI 3 flow at the end of primary PCI
• Post PCI non-hyperemic angio-derived IMR measurements. PCI

Measured at 1 year post procedure:

• MACE at 1-year follow-up (a composite end point of all-cause death, myocardial infarction, pMCS implant, target lesion revascularization, stent thrombosis, ICD implantation or HF hospitalizations) and each individual component.

Safety endpoint:

Measured at 1 month post procedure:

• Device-related SAE(s) and Stroke

Conditions

Anterior Myocardial Infarction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Subjects randomized to the control arm will be treated with standard PPCI

Subjects randomized to the control arm will be treated with standard PPCI

Group Type: NO_INTERVENTION

No interventions assigned to this group

- Treatment arm: Subjects randomized to the treatment arm will be treated with the CAT RX

Treatment arm: Subjects randomized to the treatment arm will be treated with the CAT RX

Group Type: EXPERIMENTAL

THROMBOASPIRATION WITH INDIGO SYSTEM

Intervention Type: PROCEDURE

Subjects randomized to the treatment arm will be treated with the CAT RX as previously described.

Interventions

THROMBOASPIRATION WITH INDIGO SYSTEM

Subjects randomized to the treatment arm will be treated with the CAT RX as previously described.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Age >18 and <75 years old

2. Acute anterior STEMI with ≥2 mm in two (2) or more contiguous anterior leads or ≥4 mm total ST-segment deviation sum in the anterior leads V1-V4 AND anterior wall motion abnormality noted on a diagnostic quality left ventriculogram or echocardiogram

3. Culprit lesion proximal or mid LAD at coronary angiography

4. TIMI thrombus grading > 3 or TIMI flow 0 after guidewire crossing the lesion.

5. Patient presents to the hospital between 1 - 6 hours of ischemic pain onset

6. Patient indicated for primary percutaneous coronary intervention (PPCI)

Exclusion Criteria

1. Unable to give Informed consent.

2. Life expectancy < 1 year.

3. Contraindication to PCI

4. STEMI due to stent thrombosis

5. Spontaneous coronary aretery dissection

6. Patient undergone any kind of maneuvers to restore flow before randomization

7. Unwitnessed cardiac arrest OR ≥30 minutes of cardiopulmonary resuscitation (CPR) prior to enrolment OR any cardiac arrest with impairment in mental status, cognition or any global or focal neurological deficit

8. New onset of stroke symptoms and NIHSS >2, prior to index procedure

9. Known intolerance to aspirin, clopidogrel, ticagrelor, heparin, contrast media.

10. Active severe bleeding

11. Severe hepatic/kidney impairment

12. Administration of fibrinolytic therapy within 24 hours prior to enrolment

13. Cardiogenic shock defined as systemic hypotension (systolic BP <90 mmHg or the need for inotropes/pressors to maintain a systolic BP >90 mmHg), plus one (1) of the following: any requirement for pressors / inotropes prior to arrival at the catheterization laboratory, clinical evidence of end-organ hypoperfusion, or use of IABP or any other mechanical circulatory support device

14. Inferior STEMI or suspected right ventricular failure

15. Severe valvulopathy

16. Acute cardiac mechanical complication: LV-free wall rupture OR interventricular septum rupture OR acute mitral regurgitation

Medical Conditions & History:

1. Suspected or known pregnancy

2. Suspected systemic active infection

3. History or known hepatic insufficiency prior to catheterization

4. Undergoing a renal replacement therapy

5. Chronic obstructive pulmonary disease (COPD) with home oxygen therapy or on chronic steroid therapy

6. Contraindication to perform MRI or use gadolinium [creatinine clearance (CrCl) <30 mL/min, non-compatible implant, claustrophobia]

Cardiovascular history

1. Known or evidence of prior MI, including pathologic Q-waves in non-anterior leads

2. Prior coronary artery bypass graft surgery (CABG) or LAD PCI

3. History of heart failure (documented history of EF <40% or documented hospitalization for HF within 1 year prior to screening

4. Prior aortic valve surgery or TAVR

5. Left bundle branch block (new or old)

6. History of stroke/TIA within 3 months prior to screening

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

European Cardiovascular Research Center

NETWORK

Sponsor Role: collaborator

Ceric Sàrl

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alaide Chieffo

Role: PRINCIPAL_INVESTIGATOR

San Raffaele Hospital

Locations

IRCCS Ospedale San Raffaele

Milan, Milani, Italy

Countries

Italy

Central Contacts

Phani Krishna KONDAMUDI

Role: CONTACT

pkondamudi@cerc-europe.org

+33 (0)1 60 11 17 91

Facility Contacts

Alaide Chieffo

Role: primary

cecalaide@gmail.com

+39 02.26431

Other Identifiers

TACTIC

Identifier Type: -

Identifier Source: org_study_id